NVAX (Novavax) Cyclically Adjusted PB Ratio: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVAX Novavax Inc NVAX
46 GF Score
Price $9.47
GF Value $3.18
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novavax Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novavax  (NAS:NVAX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novavax Cyclically Adjusted PB Ratio Related Terms


Novavax Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Novavax's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Cyclically Adjusted PB Ratio Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.17 1.43 1.02 4.78 0.00

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NVAX vs MAZE, SLBT, AVLN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PB Ratio falls into.


NVAX
46GF Score
Novavax Inc NVAX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Novavax's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.157/333.9520*333.9520
=-1.157

Current CPI (Jun. 2026) = 333.9520.

Novavax Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.671 241.428 5.078
201612 -0.409 241.432 -0.566
201703 -2.059 243.801 -2.820
201706 -4.074 244.955 -5.554
201709 -4.781 246.819 -6.469
201712 -6.295 246.524 -8.527
201803 -5.732 249.554 -7.671
201806 -4.596 251.989 -6.091
201809 -6.620 252.439 -8.758
201812 -8.737 251.233 -11.614
201903 -6.415 254.202 -8.428
201906 -7.902 256.143 -10.302
201909 -7.436 256.759 -9.672
201912 -5.750 256.974 -7.472
202003 -0.445 258.115 -0.576
202006 3.015 257.797 3.906
202009 1.691 260.280 2.170
202012 8.840 260.474 11.334
202103 14.031 264.877 17.690
202106 10.042 271.696 12.343
202109 6.117 274.310 7.447
202112 -4.637 278.802 -5.554
202203 0.836 287.504 0.971
202206 -5.334 296.311 -6.012
202209 -7.212 296.808 -8.115
202212 -7.370 296.797 -8.293
202303 -10.379 301.836 -11.483
202306 -8.001 305.109 -8.757
202309 -5.713 307.789 -6.199
202312 -5.139 306.746 -5.595
202403 -6.177 312.332 -6.605
202406 -2.700 314.175 -2.870
202409 -3.287 315.301 -3.481
202412 -3.889 315.605 -4.115
202503 -0.467 319.799 -0.488
202506 0.232 322.561 0.240
202509 -0.964 324.800 -0.991
202512 -0.786 324.054 -0.810
202603 -0.880 330.213 -0.890
202606 -1.157 333.952 -1.157

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Novavax (NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of $9.47 is trading 197.6% above its estimated GF Value™ of $3.18. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for NVAX:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $3.18 vs. price of $9.47 (197.6% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score

Get the complete analysis for NVAX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.47
Price
$3.18
GF Value